Hints and tips:
Related Special Reports
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...This came after Prayuth Chan-ocha, the prime minister, said on Thursday that Russian President Vladimir Putin had promised to provide Thailand with an undisclosed amount of Sputnik V vaccines under a government...
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...Pfizer’s Covid-19 vaccine, for example, needs to be stored at minus 70C....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Brunswick Group hired former Pfizer China government affairs vice-president Xi Qing as a partner in Asia....
...US outfits such as Cadwalader, Wickersham & Taft, Reed Smith, BCLP and Baker McKenzie have moved swiftly to cut both payouts for partners and salaries for more junior lawyers — going further than most UK...
...Pfizer is replacing one veteran insider with another at the helm of the company. Albert Bourla, who trained as a vet in Greece, has worked for Pfizer for 25 years....
...GBH’s price target would imply a market cap of about $217.35bn for Netflix — compared with $173.5bn at present — and would put it just ahead of where Pfizer, Mastercard, Cisco and Boeing are sitting today...
...James Beck, an attorney at Reed Smith, described the FDA’s U-turn as “remarkable” and said he could not recall a previous occasion when the agency had rescinded a warning letter....
...The spread between Pfizer’s bid and AstraZeneca’s share price reflects both a fear that the deal will not happen and concerns over the proportion of Pfizer stock that an improved offer would include – the...
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...Reed Hastings, Netflix chief executive, used a quarterly earnings letter to outline the company’s opposition to the deal, claiming it would give Comcast too much control of high-speed internet provision...
...Tim Reed, head of Health Action International, a Brussels watchdog, argues that the pharmaceutical industry needs far tougher restrictions....
...● Roche of Switzerland has appointed a senior academic as its new head of early stage research, naming John Reed, chief executive of the Sanford-Burnham Medical Research Institute in the US, to an expanded...
...A new version of its CR-V small SUV begins production in September, and it plans to renew its small Jazz at a later date....
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...Tim Reed, head of Health Action International, a Brussels-based watchdog, says: “Some codes of conduct are good. But it’s in the implementation that they fail....
...“The art world is, I think, quite excited by lots of what digital technology has to offer,” said Gregor Pryor, digital media specialist at Reed Smith, the law firm, who has worked with Artfinder....
...Frida Giannini, the creative director of Gucci, and Patrizio di Marco, the chief executive, are in the ornate restaurant of the George V hotel in Paris, posing for a portrait. They look uncomfortable....
...Honda is also expected to introduce a redesigned CR-V late next year....
...It was called EN-V (for Electric Networked Vehicle) and came in three variants with Chinese names: Xiao (“laugh”), Jiao (“pride”) and Miao (“magic”) “Miao will transport you magically and seamlessly through...
...Pfizer, the largest US drugmaker by market value, inched down 0.7 per cent to $14.54 as the stock being removed from the “conviction buy” list at Goldman Sachs....
...It was a trial – in that case, an expensive one,” says Mike Rusbridge, head of Reed Elsevier’s events business....
International Edition